Conditions: Basal Cell Carcinoma
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 18
Healthy volunteers: no

Brief summary:
This randomized, double-blind, placebo-controlled study will assess the efficacy and safety of vismodegib with surgery in participants with basal cell carcinoma.

Detailed description:

Arms:
arm 1: Participants will receive matching placebo to vismodegib capsule orally once daily for 12 weeks. arm 2: Participants will receive vismodegib 150 milligrams (mg) capsule orally once daily for 12 weeks.

Interventions: intervention 1: Placebo intervention 2: Vismodegib
Intervention descriptions: intervention 1: Participants will receive matching placebo to vismodegib for 12 weeks. intervention 2: Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks

Protocol document: